NCI-2023-08648

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation

This is a research study testing a drug called Divarasib in people who have advanced or metastatic non-small cell lung cancer (NSCLC) with a specific genetic mutation called KRAS G12C. These patients have not had treatment yet for their advanced cancer. The study is looking at how safe Divarasib is when used together with other cancer treatments, how well this combination works against the cancer, and how the drug moves and behaves in the body (pharmacokinetics). It’s an open-label study, meaning everyone knows what treatments are being given, and it’s happening at multiple hospitals and clinics. The goal is to find out if this drug combination could be a helpful new treatment option for this type of lung cancer.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

Non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

KRAS: A KRAS mutation is a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05789082

Clinical Trial Site: Sinai

To see all available clinical trials click here.